Launching a medical device or in vitro diagnostic product in the European Union is a structured and highly regulated process designed to protect patient safety and ensure product performance. With the introduction of the Medical Devices Regulation (EU) 2017/745 (EU MDR) and the In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR), manufacturers now face more comprehensive and transparent requirements before placing products on the EU market. These regulations have reshaped how medical devices are developed, evaluated, approved, and monitored throughout their lifecycle.
Understanding the launch procedure for medical devices regulation is essential for manufacturers, startups, and regulatory professionals aiming to achieve compliant market entry and long-term sustainability in Europe. The MDR and IVDR frameworks place greater emphasis on clinical evidence, traceability, and post-market surveillance, making regulatory planning a strategic activity rather than a final checklist.
The EU MDR and IVDR replaced the earlier Medical Device Directives (MDD and IVDD) to address gaps in safety oversight and regulatory enforcement. EU MDR applies to general medical devices, including implantable and software-based products, while IVDR governs in vitro diagnostic medical devices such as reagents, instruments, and test kits.
Both regulations introduce a lifecycle-based approach to compliance. This means that regulatory obligations do not end at CE marking but continue through post-market surveillance, vigilance reporting, and periodic updates to technical documentation. The regulations also increase the role of economic operators, including manufacturers, authorized representatives, importers, and distributors, making regulatory responsibility shared and traceable across the supply chain.
The revision of European medical device regulations was driven by the need to improve patient safety, restore public trust, and ensure consistent regulatory control across member states. High-profile safety incidents exposed weaknesses in the old directive-based system, particularly around clinical evidence and notified body oversight.
Under MDR and IVDR, manufacturers must demonstrate stronger scientific and clinical justification for their products. Unique Device Identification (UDI), EUDAMED registration, and stricter post-market obligations were introduced to enhance traceability and transparency. As a result, the launch procedure for medical devices regulation is now more data-driven and evidence-focused than ever before.
Device classification is the foundation of the regulatory pathway. Under MDR and IVDR, classification rules have been expanded, leading many devices to move into higher risk classes. Classification determines the conformity assessment route, the level of notified body involvement, and the depth of technical documentation required. An incorrect classification can delay approvals and increase compliance risk.
A compliant Quality Management System is mandatory for most medical devices and IVDs. ISO 13485 alignment is expected under both MDR and IVDR, covering design controls, risk management, supplier control, production processes, and corrective actions. The QMS must be implemented and maintained before CE marking and must support ongoing regulatory compliance.
Technical documentation serves as the core evidence of compliance. It includes device descriptions, intended use, risk management files, design and manufacturing information, and verification and validation data. MDR and IVDR require more detailed and structured documentation compared to previous directives, with a strong focus on traceability between risks, controls, and clinical data.
Clinical evaluation is a central requirement under MDR, while IVDR emphasizes clinical evidence through performance evaluation. Manufacturers must demonstrate that their devices achieve the intended clinical benefit while maintaining acceptable safety. This may involve clinical investigations, performance studies, or robust literature-based justification. Legacy devices often require updated clinical data to meet current regulatory expectations.
Most medium- and high-risk devices require assessment by a notified body. Under MDR and IVDR, notified bodies operate under stricter designation criteria, leading to limited availability and longer review timelines. Early engagement with a notified body is critical to avoid delays during the launch phase.
The launch procedure for medical devices regulation begins with regulatory strategy development, including classification, market scope, and conformity assessment planning. Manufacturers then establish or update their quality management system and compile technical documentation aligned with MDR or IVDR annexes.
Next, conformity assessment activities are initiated. This may include audits, technical file reviews, and clinical data evaluations conducted by a notified body where applicable. Once conformity is demonstrated, the CE marking can be affixed, and the device can be registered in EUDAMED along with relevant economic operator information.
The launch does not conclude with market placement. Post-market surveillance plans must be implemented to collect real-world data, manage complaints, and report incidents. Periodic Safety Update Reports and vigilance reporting ensure continuous regulatory oversight throughout the product lifecycle.
Many manufacturers encounter difficulties during the transition from directives to MDR and IVDR. Common challenges include gaps in clinical evidence, underestimating notified body timelines, and misalignment between existing quality systems and new regulatory expectations. Startups may struggle with resource planning, while established companies often face portfolio-wide remediation efforts.
Another challenge is interpreting regulatory requirements consistently across product lines and markets. The increased documentation burden and evolving guidance from European authorities require ongoing regulatory intelligence and adaptability.
Navigating EU MDR and IVDR requirements requires a deep understanding of regulatory frameworks, practical implementation strategies, and evolving guidance. Regulatory experts play a critical role in helping manufacturers interpret requirements correctly, structure documentation efficiently, and plan realistic timelines. Organizations such as Operon Strategist contribute regulatory insight by supporting compliance planning, documentation alignment, and lifecycle management within the European regulatory environment.
The launch procedure for medical devices regulation under EU MDR and IVDR represents a significant shift toward greater accountability, transparency, and patient safety. Manufacturers must adopt a proactive and structured approach that integrates regulatory compliance into product development and lifecycle management. By understanding classification rules, quality system requirements, clinical evidence expectations, and post-market obligations, organizations can achieve compliant and sustainable market entry in Europe. A well-planned regulatory strategy not only supports successful CE marking but also strengthens long-term market access and global competitiveness.
© 2025 Crivva - Hosted by Airy Hosting Managed Website Hosting.
